Targeting Natriuretic Peptide Levels in Heart Failure with Therapy: Does "X" Really Mark the Spot?

Area of Science:

• Cardiology
• Biomarker Research
• Heart Failure Management

Background:

• Natriuretic peptides (e.g., BNP, NT-proBNP) are elevated in heart failure (HF) due to end-diastolic stress.
• These biomarkers are crucial for HF diagnosis and prognosis, and their levels decrease with guideline-directed medical therapy (GDMT).
• Previous small studies suggested potential benefits of biomarker-guided HF therapy.

Purpose of the Study:

• To explore the controversial role of biomarker-guided management in patients with heart failure (HF) and reduced ejection fraction.
• To evaluate if intensifying HF care based on natriuretic peptide levels improves clinical outcomes.

Main Methods:

• The Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) trial, a large randomized controlled study, was conducted.
• It compared biomarker-guided therapy against usual care in HF patients.

Main Results:

• The GUIDE-IT study did not find biomarker-guided therapy to be more effective than usual care.
• There was no significant improvement in the primary endpoints of HF hospitalization or cardiovascular mortality in the biomarker-guided group.
• Natriuretic peptide levels are important for HF diagnosis and prognosis, but guiding therapy by them did not enhance clinical outcomes in this study.

Conclusions:

• Biomarker-guided strategies, specifically using natriuretic peptides, did not demonstrate clinical benefit over usual care for patients with HF and reduced ejection fraction.
• Future research should investigate biomarker guidance in different clinical settings and for other HF phenotypes, such as preserved ejection fraction.
• Natriuretic peptides remain vital tools for HF diagnosis and prognosis.